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Abstract
Cases of chronic kidney disease (CKD), including CKD in pregnant women, have increased globally in recent years. CKD
during pregnancy is associated with a higher risk of adverse outcomes, including gestational hypertension, preeclampsia,
intrauterine growth restriction, and preterm birth, among others. Nutrition plays a significant role in many metabolic and
physiological changes during pregnancy. Women with CKD are at increased risk of nutrition deficiencies and metabolic
issues than women without CKD. Currently, we lack evidence regarding metabolic and nutritional adaptations during
pregnancy in women with CKD and how these adaptations relate to perinatal outcomes. In this review, dietary and
supplementation recommendations for CKD in adults and pregnant women are summarized from current clinical guidelines.
We present the main nutrition care practices that have been studied in CKD pregnancies. This review will be helpful to
health professionals as a preliminary reference for nutrition assessment and therapy in pregnant women with CKD.
Introduction
The frequency of chronic kidney disease (CKD) during
pregnancy has increased. This could be related to the higher
prevalence in CKD reported in recent years, the improve-
ment of medical treatment in CKD adults, and a better
kidney function assessment during pregnancy [1–3].
Pregnant women with CKD have specific nutritional
needs and are at higher risk of adverse perinatal outcomes.
There are currently no established guidelines to address
nutrition therapy in this group. In this review, we aim to
summarize established nutritional recommendations for
nonpregnant individuals with CKD [4–6] and those for
healthy pregnant women [7–9], and present data from stu-
dies done in pregnant women with CKD.
Nutrition intervention for pregnant women
with CKD
Nutrition therapy goals for pregnant women with CKD
include to meet energy and nutrient needs for optimal fetal
growth and development while promoting adequate meta-
bolic control; to make individual recommendations for
vitamin and mineral supplementation; and to promote a
healthy lifestyle to improve maternal and fetal health.
Energy and macronutrient recommendations in
pregnant women with CKD
Energy recommendations
CKD Resting energy expenditure (REE) appears to be higher
in adults with CKD due to renal replacement therapy, poorly
controlled diabetes mellitus (DM), severe hyperparathyroidism
(HPT), and inflammation. In nondialyzed patients, REE tends
to be equal or even lower than that of healthy individuals [10].
In stages 3–4 of CKD, the recommended energy intake is
96.2–146.4 kJ/kg/day (23–35 kcal/kg/day) using current
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weight [5]. During dialysis, American guidelines suggest to
use 125.5–167.4 kJ/kg/day (30–35 kcal/kg/day), while Eur-
opean guidelines recommend 125.5–167.4 kJ/per ideal body
weight/day (30–40 kcal/kg/day) [5, 6].
CKD and pregnancy To estimate energy requirements in
pregnant women, energy prediction equations can be used
with pregestational weight, adding pregnancy energy needs
(355.6 kJ/day or 85 kcal/day, 1192.4 kJ/day or 285 kcal/day,
and 1987.4 kJ/day or 475 kcal/day during the 1st, 2nd, and
3rd trimester, respectively) [8, 7].
Gestational weight gain is an important indicator of
energy balance and should be monitored. In healthy
pregnancy, weight gain is determined by the pregestational
body mass index. Institute of Medicine’s gestational weight
gain recommendations range from 5 kg (in obesity) to
18 kg (in underweight). The Intergrowth Consortium
suggests a gestational weight gain of 13.6 kg in normal-
weight women [11, 12].
In women with advanced CKD stages, weight gain
assessment is a challenge. Data from dialysis patients have
reported a weight gain of 1–1.5 kg during the first trimester
and 0.5 kg/week in the second and third trimesters [13].
Several reports of pregnant women undergoing dialysis
with optimal perinatal outcomes showed a total weight gain
between 5.2 and 12 kg, with the highest gain in patients
who received nutrition therapy [14–16].
In CKD pregnant women in stages 1 and 2, it seems prudent
to use energy intake recommendations for healthy pregnant
women. During stages 3 and 4, energy recommendations for
nonpregnant CKD adults could be used, using pregestational
weight and adding the energy cost of pregnancy. If
pregestational weight is not reliable, current dry weight can
be used without adding pregnancy requirements. For pregnant
women under HD and peritoneal dialysis (PD), the Italian
study group suggests 146.4 kJ/kg (35 kcal/kg) and 104.6 kJ/kg
(25 kcal/kg) with pregestational weight, respectively, and
adding the energy cost of pregnancy [17]. Reported cases of
pregnancies undergoing HD showed that an intake of
125.5–146.4 kJ/pregestational (30–35 kcal/kg) plus
1255.2–1674.4 kJ (300–400 kcal/day) from the second trime-
ster was positively associated with maternal weight gain, lower
incidence of small-for-gestational age (SGA), and less frequent
neonatal intensive care unit hospitalization [14–16, 18, 19].
Protein recommendations
CKD For adults with CKD with a glomerular filtration rate
(GFR) below 50 ml/min per 1.73 m2, the protein intake
recommendation is 0.6–0.8 g/kg/day. When GFR is
<20 ml/min per 1.73 m2, a very low-protein diet may be
prescribed (0.3–0.5 g/kg/day) with ketoacid analog sup-
plementation [5].
In adults under dialysis, protein intake recommendations
range from 1.1 to 1.3 g/kg/day, using ideal or current dry
body weight. Protein intake should be increased with more
intensive HD [6]. At least 50% of dietary protein should be
of high biological value [4, 6].
Signs, symptoms, and markers related to uremic syn-
drome and renal function (GFR, BUN, serum creatinine,
and proteinuria) should be monitored to individualize
protein intake recommendations.
CKD and pregnancy Protein requirements in pregnancy are
71 g/day or 1.1 g/kg/day. Adult protein requirements can be
used (0.8 g/kg of pregestational weight/day) if additional
protein needs of pregnancy are added (+1, 9, and 31 g/day
during the 1st, 2nd, and 3rd trimester, respectively) [7, 9].
For pregnant women in CKD stages 1 and 2, recom-
mended protein intake may be similar to that for a healthy
pregnancy. In advanced CKD stages and under dialysis,
protein recommendations for adults with CKD may be used,
while adding the extra needs of pregnancy. In stages 3–5, a
moderate-protein-restricted plant-based diet (0.6–0.8 g/kg/
day of protein) plus keto-analogs (1 tablet/8–10 kg) showed
a lower frequency of early preterm delivery, very low birth
weight (LBW) (<1500 g) and SGA infants [20–23]. In
different reported case series of pregnant women under HD, a
protein intake of 1.2–1.5 g/kg of ideal body weight/day plus
6–10 g/day was related with optimal plasmatic nitrogen
compounds levels, controlled blood pressure, reduced
proteinuria, and improved plasmatic albumin and phosphorus
[14, 15, 18]. Vidal et al. observed an optimal maternal weight
gain, good calcium–phosphate metabolism, and favorable
neonatal outcomes with 1.1–1.2 g/kg/day (pregestational dry
weight/day) of protein during the first trimester and 1.5 g/kg
(current body weight) in the second and third trimesters [16].
Espinoza et al. recommended a higher amount of protein
(1.8–2 g/kg/day) and added intradialytic amino acids in cases
of low intake, observing a lower incidence of SGA infants
[19]. According to the Italian study group, protein intake
recommendations for HD and PD should be 1.2 and 1.4 g/kg/
day pregestational weight, respectively [17].
Lipid recommendations
CKD CKD is associated with dyslipidemia, showing
similar characteristics in early and advanced kidney failure
[low high-density lipoproteins, normal or low total choles-
terol, high low-density lipoprotein cholesterol and increased
triglycerides (TG)]. Lipid profile in patients with PD tends
to be more atherogenic [24, 25].
Lipid and saturated fat intakes for individuals with CKD
should be maintained below 30 and 10% of total energy
intake (TEI), respectively [25]. In hypertriglyceridemia, a
low-fat diet (<15% TEI) is suggested with an accompanying
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reduction in mono and disaccharide intake and the use of
fish oil to replace long-chain TGs [25]. In case of
hypercholesterolemia, monounsaturated fat recommended
intake is >10%, saturated fatty acid <10%, and cholesterol
intake <300 mg/day [6].
CKD and pregnancy Lipid metabolism during pregnancy is
characterized by an accumulation of fat in maternal depots
during early pregnancy and the later development of
hyperlipidemia due to increasing lipolysis and mobilization
of TG [26].
No lipid status has been reported in CKD pregnant
women. In our case series of pregnant women with CKD
(without dialysis), mean serum cholesterol and TG were
246.6 ± 116.7 mg/dL and 277.0 ± 187.0 mg/dL, respec-
tively, in the second trimester, and 277.1 ± 129.3 mg/dL
and 341.1 ± 190.6 mg/dL, respectively, in the third trimester
(n= 48) (unpublished data).
The total fat intake recommendation in pregnancy is
<30–35% of TEI [7]. Omega 3 fatty acids play an important
role in retinal and neurological fetal development. European
recommendations for EPA+DHA are 250 mg/day and an
extra 100–200 mg/day of DHA [27]. Linoleic and α-
linolenic fatty acids intake recommendations are 13 g/day
and 1.4 g/day, respectively [7, 27, 28]. Oily fish (salmon,
trout, sardines, and tuna) consumption should be increased
during pregnancy (250–300 g/week) [7, 8].
Carbohydrate recommendations
Glucose metabolism is frequently impaired in CKD due to
reduced insulin-mediated glucose uptake in skeletal muscle.
Insulin resistance is more frequent in advanced CKD stages.
Although some patients can compensate for insulin resis-
tance by increasing insulin secretion, defects in insulin
secretion are common [29].
In adults with CKD and DM, carbohydrate intake recom-
mendations should be addressed to manage hyperglycemia,
aiming to achieve glycemic control (HbA1C < 7%) [5].
Early pregnancy is characterized by an increase in
insulin sensitivity, while an insulin resistance state
develops during late pregnancy to prioritize the use of fats
for energy, sparing carbohydrates for the fetus [30]. If
CKD pregnant women have previous DM or GDM, gly-
cemic control is the main goal of treatment (goal:fasting
capillary glucose ≤ 95 mg/dL and 1-h postprandial capil-
lary glucose ≤140 mg/dL) [31].
In a healthy pregnancy, acceptable carbohydrate
recommended intake is 45–65% of TEI [28], while fiber
intake recommendation is 28 g/day [28]. In women with
previous DM or GDM, carbohydrate recommendations
should be individualized [31]. The most accepted strategies
include monitoring carbohydrate intake (‘carb counting’).
Three meals and 2–3 snacks are preferred while promoting
healthy carbohydrate consumption (low-glycemic index
foods and/or high-fiber food sources) and avoiding added
sugars and processed foods [32, 33]. A minimal carbohy-
drate intake of 175 g/day during pregnancy seems appro-
priate [28].
Fluids
CKD is associated with hydroelectrolytic disturbances. When
GFR is below 20mL/min, the kidney loses its capacity to
concentrate or dilute the urine [34]. Sodium and water
recommendations should be individualized based on diuresis
and interdialytic weight gain in dialysis patients. Interdialytic
weight gain has been suggested to be 4–4.5% of dry weight
[5]. Fluid intake recommendation for a healthy pregnancy is
3 L/day [28]. Table 1 summarizes energy and macronutrient
recommendations for pregnant women with CKD.
Vitamin and mineral recommendations
In early CKD stages, micronutrient intake recommenda-
tions are similar to those for a healthy pregnancy. Specific
recommendations are now needed for those at more
advanced stages of CKD and pregnant women on dialysis.
Table 2 summarizes vitamin and mineral recommenda-
tions for healthy pregnant women and for nonpregnant
CKD individuals.
Calcium, vitamin D, and phosphorus
CKD CKD is characterized by disturbances in mineral,
vitamin D, and parathyroid hormone (PTH) metabolism
[35]. As GFR declines, a fall in the activity of the renal
vitamin D 1α-hydroxylase enzyme is observed. As a result,
the conversion of vitamin D to its active form, 25-
hydroxyvitamin D (25-OH-D), is impaired. Consequently,
vitamin D-dependent calcium absorption is limited, hypo-
calcemia occurs, and PTH production increases in a coun-
terregulatory attempt to release calcium from bone stores. In
contrast, phosphorus excretion is decreased, triggering an
increased production of fibroblast growth factor, which also
suppresses 1α-hydroxylase. The release of bone mineral
stores exacerbates hyperphosphatemia, which promotes
further production of PTH [35, 36].
KDIGO recommends measuring serum 25-OH-D, cal-
cium, phosphorus, PTH, and alkaline phosphatase activity
at least once in adults with CKD stage 3 and above, and
then annual reassessment if levels are within normal
parameters [3]. Clinical signs and symptoms of hyperpho-
sphatemia (Itching, bone pain, and vascular calcification)
related to the advanced stages of CKD should be assessed
and monitored [36].
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During stages 3–5 and HD, the Academy of Nutrition and
Dietetics suggests a total elemental calcium intake (from the
diet, supplements, and phosphate binders) <2 g/day in CKD
patients [5].
Dietary phosphorus should be restricted to 800–1000 mg/
day when serum phosphorus levels are >4.6 mg/dL (stages
3–4) or >5.5 mg/dL (stage 5) [5]. Dietary phosphorus
restriction is also needed when plasma PTH is >70 pg/ml in
more than two consecutive measurements. Dietary strate-
gies for phosphorus restriction include to avoid organic (i.e.,
dairy, meats, poultry, fish, and grains) and inorganic
(preservatives and additives) sources [36].
Vitamin D supplementation with 800–1000 IU of
cholecalciferol is indicated when serum 25-OH-D is below
30 ng/ml or in stages 4–5 with severe and progressive
HPT [36].
In stages 3–4, active oral supplementation with calcitriol
or vitamin D analogs is indicated when plasma PTH is high
and in patients with serum corrected total calcium <9.5 mg/
dL and serum phosphorus <4.6 mg/dL [5].
CKD and pregnancy During a healthy pregnancy, calcium
absorption is stimulated to meet increased requirements [37].
Increased production of 1,25[OH]2D secondary to
1-alpha-hydroxylase placental activity is observed. Vitamin D
homeostasis is characterized by an increase in maternal cal-
citriol, enhanced availability of maternal 25-OH-D, and
increase of maternal vitamin D-binding protein concentrations
[37]. The American College of Obstetricians and Gynecolo-
gists considers levels of circulating 25-OH-D below 32 ng/mL
during pregnancy as deficient [38].
There are no reports of serum PTH and 25-OH-D
concentrations in CKD pregnant women. In our case
series of pregnant women with CKD (stages 1–4 without
dialysis), we observed PTH levels in the second and third
trimesters of 55.3 ± 107.6 pg/ml and 47.7 ± 36.9 pg/ml,
respectively. These concentrations exceed normal ranges
for a healthy pregnancy but are within normal ranges
reported in CKD adults (Table 3). Plasma 25-OH-D
concentrations were 27.6 ± 11.7 ng/ml (second trimester)
and 28.5 ± 10.7 ng/ml (third trimester). During the second
and third trimesters, 22% (n= 8/36) and 19% (n= 5/26)
of women had low 25-OH-D (<20 ng/mL), respectively.
We observed a positive correlation between PTH net
change from the second to the third trimester with plasma
phosphorus concentration in the third trimester (r= 0.43,
p= 0.020) (unpublished data). Table 3 shows the
reference values for bone mineral metabolism biochem-
ical markers in CKD and during healthy pregnancy.
In healthy pregnant women with adequate vitamin D stores
and normal PTH levels, calcium intake should be
1000–1300mg/day [27, 39]. The WHO recommends
1.5–2.0 g/day of elemental calcium in women with a high





CKD 3–5 stages Dialysis
Energy (kJ/kg/day)a First 96–146+ 289 kJ 105–146+ 289 kJb
Second 96–146+ 1100–1423 kJ 105–146+ 1100–1423 kJb
Third 96–146 + 1891–2096 kJ 105–146+ 1891–2096 kJb
Protein (g/kg/day)a First 0.6–1.0+ 0.7 g 1.1–1.5+ 0.7 g
Second 0.6–1.0+ 9.6 g 1.1–1.5+ 9.6 g
Third 0.6–1.0+ 31.2 g 1.1–1.5+ 31.2 g
Carbohydrates % TEI 35–65
Fiber (g/day) 20–30
Lipids % TEI ≤30
Saturated fatty acids % TEI <7–10c
Monounsaturated fatty acids % TEI 10–20d
Polyunsaturated fat % TEI ≤10
Linoleic acid (g/day) 13




bDue glucose absorption from dialysate, the lower range is suggested for peritoneal dialysis
cIn case of dialysis apply 7% of TEI
dIn case of dialysis apply 20% of TEI. From references [4–9, 27, 28]
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calcium intakes [40]. Phosphorus intake recommendation for
healthy pregnancy is 700–1250mg/day [27, 39]. High
prevalence of low serum 25-OH-D are frequently reported
during pregnancy, so 25-OH-D assessment seems important to
decide if supplementation is necessary [37]. Vitamin D doses
of 1000–2000 IU/day as supplements could be considered safe
during pregnancy [38].
Calcium supplementation has been reported in isolated
case studies, ranging from 300 to 1500 mg/day [14, 16].
Due to more frequent dialysis sessions, phosphorus
restriction, and phosphate binders use might not be needed
in CKD pregnancies [2]. Although oral vitamin D
supplementation is suggested in CKD pregnant women,
very low doses have been used (10–250 UI/day) [14, 16].
Vitamin D analogs have been given intravenously to
pregnant women undergoing dialysis, but it is not clear
whether they have any adverse effect on the fetus. Once 25-
OH-D reaches its optimal levels, a vitamin D-containing
multivitamin should be continued [41].
Iron, folic acid, and cobalamin
CKD Anemia in women with CKD is diagnosed when
hemoglobin levels are below 12.0 g/dL, and it is associated
with insufficient production and release of erythropoietin
(EPO), so in most cases, anemia is characterized as being
hyperproliferative, normochromic, and normocytic [42].
Besides insufficient EPO production, iron deficiency is the
most common reversible cause of chronic anemia in CKD
patients. An in-depth assessment that includes a complete
blood count, absolute reticulocyte count, serum ferritin
level, serum transferrin saturation (TSAT), serum vitamin
B12, and folate levels should be performed [42]. KDIGO
suggests monitoring nonanemic CKD patients when clini-
cally indicated or annually (stage 3), twice per year (stages
4–5 without dialysis), or every 3 months (stage 5 with
dialysis). Iron status should be monitored every 3 months
with more frequent assessments in individuals on HD and
receiving erythropoiesis-stimulating agents (ESA) [43].
Table 2 DRI and DRV of
micronutrients for healthy
pregnant women over 18 years
and for nonpregnant CKD
individuals.




Calcium (mg) 950–1000 <2000 <1500–2000
Phosphorus (mg) 550–700 800–1000 800–1000
Potassium (mg) 3500–4700 ≤2400 3700–5200
Sodium (mg) 1500 <2400 2000–2300
Iron (mg) 16–27 15c 15c
Zinc (mg) 11–12d 8–12 8–12
Magnesium (mg) 300–350 290–300 200–300
Vitamin D (UI) 600 800–1000 800–1000f
Vitamin A (µg) 700–770 550 700–900
Vitamin C (mg) 85–105 30–60 75–90
Vitamin B1 (mg) 0.8–1.4g 1.1 1.1–1.2
Vitamin B2 (mg) 1.4–1.9 1.1 1.1–1.3
Vitamin B3 (mg) 13.4–18g 14 14–16
Vitamin B6 (mg) 1.8–1.9 5 10
Vitamin B12 (µg) 2.2–4.5 >2–3 2.4
Biotin (µg) 30–40 30–100 30
Folic acid (mg) 0.6 >1 1.0
DRI dietary references intakes, DRV dietary references values, ESRD end-stage-renal disease
aRecommended dietary allowance (RDA) and Populations reference intake (PRI)
bPregestational body weight
cAccording iron studies and erythropoiesis-stimulating agent use
dBased on the average for zinc recommendation according phytates consumption and the amount add
for pregnancy
e1,25(OH)2D3 if low serum levels
fAdjust dose based on phosphorus, calcium, PTH levels
gFor each 2000 kcal. From refs. [4, 5, 27, 28]
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KDIGO recommends IV or oral iron trials in adults with
or without ESA therapy if the goal is to increase Hb without
starting ESA treatment, or to decrease ESA dose, and if
transferrin saturation is <30% and ferritin are <500 ng/ml
[42]. For HD individuals, the recommendation is 50–60 mg
of intravenous iron per week [43]. Cobalamin and folic acid
supplementation are recommended if the mean corpuscular
volume is >100 ng/ml and if serum levels of these nutrients
are below normal values [5].
CKD and pregnancy The World Health Organization
(WHO) defines anemia during pregnancy as Hb < 11 g/dL
or hematocrit < 33% at any time during the pregnancy [44].
Physiologic anemia of pregnancy reflects an expansion of
plasma volume of 50%. Globally, the most common cause
for anemia of pregnancy is iron deficiency and is related to
increased iron requirements. Iron-deficiency anemia is
associated with higher rates of preterm birth, LBW, and
SGA newborns [44].
Inadequate intake of folic acid is associated with a higher
risk of neural tube defects, LBW, and SGA. Maternal
vitamin B12 status affects fetal growth and development,
and its low levels are associated with some metabolic
alterations and impaired neurodevelopment [44]. In CKD
pregnant women, anemia might also be related to a higher
risk of prematurity, LBW, and adverse perinatal outcomes
[1]. Table 3 shows the reference values for iron status
markers in CKD and during a healthy pregnancy.
The WHO recommends supplementing 30–60 mg/day of
elemental iron daily and 400 µg/day of folic acid starting
3 months before pregnancy. In the case of anemia, 120 mg/
day of oral iron is recommended [45, 46]. Iron IV
supplementation is considered when oral iron intolerance
is reported in severe anemia (<8 g/dL) [44]. Cobalamin
supplementation is not routinely recommended except for
vegetarian/vegan women or those with a very low intake of
animal products [8].
Oral iron supplementation is safe in CKD pregnancies
under HD. IV iron might be used in dialysis during
pregnancy with caution. Cabiddu suggests to use
20–30 mg/day of IV elemental iron (iron gluconate) until
transferrin saturation reaches 30% and serum ferritin
200–300 ng/mL [17]. Folic acid needs are higher in CKD
pregnancies; supplementation has been recommended with
doses ranging between 1 and 5 mg/day, considering the
higher doses for pregnant women receiving HD [2, 41].
Sodium and potassium
In CKD adults, sodium and potassium recommendations
should be individualized based on serum concentrations,
blood pressure, medications, hydration status, and kidney
Table 3 Reference values for
biochemical markers assessment
in CKD and in pregnancy.








Calcium (mg/dL) 9–10.5 8.8–10.6 8.2–9.0 8.2–9.7
Phosphorus (mg/dL) 3–4.5 3.1–4.6 2.5–4.6 2.8–4.6
Vitamin D
25 hydroxycholecalciferol (pg/mL)
30–65 20–65 72–160 60–119





Alkaline phosphatase (IU/L) 30–85 17–88 25–126 38–229
Iron status
Hemoglobin (g/dL) 11–12 ≥11.0 ≥10.5 ≥11.0
Hematocrit (%) 37–47 ≥33 ≥32 ≥33
Serum iron (µg/dL) 50–170 72–143 44–178 30–193
Ferritin (ng/mL) Not dialysis >30
HD ≥ 20—PD > 100
6–130 2–230 0–116
Total iron binding capacity (TICB)
(µg/dL)
250–420 278–403 – 359–609
Transferrin saturation (%)a ≥20 Not reported 18–92 9–98
HD hemodialysis, PD peritoneal dialysis
aMeasure when clinically stable, not measure in acute illness. Pregnancy references adapted from: Abbassi-
Ghanavati, Greer, Cunningham. Pregnancy and Laboratory Studies. Obstet Gynecol. 2009;114:(6)1326–31.
From refs. [36, 42]
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function. Clinical signs and symptoms of hyperkalemia
(tremor, muscle weakness, dyspnea, bradycardia, arrhyth-
mia, and nausea) should be assessed and monitored. In
hyperkalemic adults with CKD, dietary intake of potassium
<2.4 g/day is recommended. Restriction of some fruits,
vegetables, and other foods rich in potassium (processed
foods with chemical potassium compounds) might be
needed [5].
In CKD, sodium intake recommendation should be
maintained at <2.4 g/day by limiting the consumption of
processed meats, smoked foods, ready-to-use seasonings
and dressings, instant soups, preservatives, and salt addi-
tives [5].
In a group of pregnant women under HD (18–24 h/
week), Vidal et al. offered 3–4 g/day of salt and 3 g of
potassium, among other recommendations, reporting posi-
tive perinatal outcomes [16].
Conclusions
Given the lack of specific research on this population, it
is possible to make adaptations to the guidelines used for
healthy pregnant and for nonpregnant individuals with
CKD. The role of the renal nutritionist is key in tailoring
energy and nutrient intakes to promote maternal and fetal
health and metabolic control. More research is urgently
needed to develop nutritional guidelines for this
population.
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